Leonard Heffner
Overview
Explore the profile of Leonard Heffner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, et al.
Blood Adv
. 2020 Feb;
4(3):449-457.
PMID: 32012214
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label,...
2.
Gokbuget N, Kantarjian H, Bruggemann M, Stein A, Bargou R, Dombret H, et al.
Blood Adv
. 2019 Oct;
3(20):3033-3037.
PMID: 31648325
Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy...
3.
Mato A, Wierda W, Davids M, Cheson B, Coutre S, Choi M, et al.
Haematologica
. 2019 Mar;
104(11):2258-2264.
PMID: 30923097
The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter's transformation chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a analysis of a phase II...
4.
Wierda W, Byrd J, Davids M, Furman R, Cheson B, Barr P, et al.
Br J Haematol
. 2018 Nov;
185(5):961-966.
PMID: 30478940
No abstract available.
5.
Coutre S, Choi M, Furman R, Eradat H, Heffner L, Jones J, et al.
Blood
. 2018 Jan;
131(15):1704-1711.
PMID: 29305552
B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown....
6.
Topp M, Gokbuget N, Stein A, Zugmaier G, OBrien S, Bargou R, et al.
Lancet Oncol
. 2014 Dec;
16(1):57-66.
PMID: 25524800
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19, an antigen consistently expressed on B-lineage...
7.
Reece D, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, et al.
Blood
. 2014 Sep;
124(16):2498-506.
PMID: 25202139
CAN2007 was a phase 1/2 study of once- and twice-weekly single-agent bortezomib in relapsed primary systemic amyloid light chain amyloidosis (AL) amyloidosis. Seventy patients were treated, including 18 and 34...
8.
Reece D, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, et al.
Blood
. 2011 May;
118(4):865-73.
PMID: 21562045
This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic AL amyloidosis evaluated the recommended (maximum planned) doses identified in phase 1 testing (1.6 mg/m² once weekly...
9.
Lima L, Bernal-Mizrachi L, Saxe D, Mann K, Tighiouart M, Arellano M, et al.
Cancer
. 2011 Mar;
117(6):1245-52.
PMID: 21381013
Background: The current study was conducted to compare simultaneously obtained bone marrow (BM) cytogenetics (CTG), peripheral blood (PB) and BM fluorescence in situ hybridization (FISH), and quantitative real-time polymerase chain...